For decades, a key number has guided glaucoma treatment decisions: an intraocular pressure (IOP) of 22 mm Hg. But emerging research suggests this benchmark may be an oversimplification, potentially leading to delayed diagnoses and treatment for some patients. A new study published in JAMA Ophthalmology highlights a growing understanding of the relationship between IOP and glaucoma risk, revealing a continuous link rather than a definitive cutoff point.
Glaucoma, a leading cause of irreversible blindness, damages the optic nerve, often due to elevated pressure inside the eye. Early detection and management of IOP are crucial to slowing disease progression. However, the traditional reliance on the 22 mm Hg threshold may not be the most effective approach, according to researchers.
The study, led by Ashley Polski, MD, of the department of ophthalmology at Moran Eye Center, University of Utah, analyzed electronic health record data from over 184,000 eyes across seven academic centers within the Sight Outcomes Research Collaborative database. Researchers examined treatment initiation – defined as a new IOP-lowering prescription within a week, laser treatment within four weeks, or glaucoma surgery within eight weeks – at varying IOP levels. The analysis encompassed more than 1.8 million clinic visits.
The findings revealed a clear trend: the likelihood of treatment increased as IOP rose from 17 mm Hg to 21 mm Hg. However, the researchers observed a “larger increase” in treatment initiation at 22 mm Hg, suggesting clinicians historically adhere to this specific threshold. “More recently, numerous studies have highlighted a continuous (rather than dichotomous) association between IOP and glaucoma risk — meaning that the risk of glaucoma increases with rising IOPs, even at levels below 22 mm Hg,” Dr. Polski and colleagues wrote. This means that glaucoma risk doesn’t suddenly appear at 22 mm Hg; it increases incrementally with any rise in IOP.
This continuous relationship challenges the notion of a hard cutoff and suggests that even IOP levels below 22 mm Hg can contribute to glaucoma development. The researchers emphasize that there is “no clinical basis to support a true IOP cutoff of 22 mm Hg in glaucoma decision-making.”
The implications of these findings are significant for ophthalmological practice. The study suggests that clinicians may benefit from moving away from a rigid IOP cutoff and adopting a more nuanced approach to risk assessment. “In the future, implementation of user-focused clinical decision support systems could help to reduce clinician reliance on heuristics and maximize clinical decision-making in ophthalmology and beyond,” the authors noted.
The Evolution of Understanding IOP and Glaucoma
The historical reliance on the 22 mm Hg threshold stems from earlier research, but our understanding of glaucoma has evolved considerably in recent decades. Factors beyond IOP, such as optic nerve anatomy and blood flow, also play a crucial role in disease development. This more holistic view necessitates a shift in how glaucoma risk is evaluated.
What This Means for Patients
Patients concerned about glaucoma should discuss their individual risk factors with their ophthalmologist. Regular eye exams, including IOP measurement and optic nerve evaluation, remain essential for early detection. The findings of this study underscore the importance of open communication between patients and their doctors to ensure the most appropriate and personalized treatment plan. It’s important to remember that glaucoma often has no early symptoms, making regular checkups even more critical.
The researchers hope their work will encourage the development of clinical decision support tools that integrate the latest research on IOP and glaucoma risk, helping clinicians make more informed treatment decisions. Further research is needed to refine these tools and determine the optimal approach to glaucoma management for diverse patient populations.
Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you discussed your glaucoma risk with your doctor? Share your thoughts in the comments below.
